ClinicalTrials.gg
CompletedNCT06419608Updated Oct 14, 2026

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

A Phase 2 interventional study of BHV-7000 and Placebo in Major Depressive Disorder, sponsored by Biohaven Therapeutics Ltd.. Completed at 62 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Biohaven Therapeutics Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
225th of 1,323
336 · median 70
Started
2024
with 69 others
Phase 2
271 of 1,500
45 open now
Registered
1,325th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 225th largest by enrollment of the 1,323 interventional ones that give a count, is one of 70 that started in 2024, is one of 271 in phase 2, and was the 1,325th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • depression
  • depressed
  • depressive disorder
  • major depression
  • major depressive episode
  • antidepressant
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Subjects experiencing a moderate to severe episode of depression.
  2. Subjects experiencing a current episode of depression for at least 2 months.
  3. Subjects must be willing to discontinue all psychotropic medications (other medications to treat depression) before entering the study.
  4. Male and Female participants 18 to 75 years of age at the time of consent.
  5. (BMI) must be ≥ 18 kg/m2 and ≤ 35 kg/m2.

Key Exclusion Criteria:

  1. Subjects taking more than 2 medications (other than benzodiazepines and medications targeting insomnia) to treat depression at the screening visit.
  2. Subjects with a history of bipolar disorder, schizophrenia, or other neuropsychiatric conditions that may interfere with the conduct of the study.
  3. Subjects with a history of medical conditions that may interfere with the conduct of the study.
  4. Females who are pregnant, breastfeeding or planning to become pregnant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
336 participants (actual)

Study arms

  • Experimental
    BHV-7000

    Drug: BHV-7000

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • BHV-7000 75 mg taken once daily for 6 weeks

  • DrugPlacebo

    Matching placebo taken once daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change in Montgomery- Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6

    The MADRS is a clinician- rated scale to assess depressive symptoms which consists of 10 items. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). A higher score represents a higher severity of the level of depression (total scores range from 0 to 60).

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change in Clinical Global Clinical Impression - Severity Scale (CGI-S) total score

    The CGI-S is a clinician-rated scale to assess disease severity. The scale is scored on 8-point scale (0 \[not assessed\] to 7 \[severe\]). A higher score represents a higher severity illness.

    Time frame: Baseline to Week 6

  2. Change in Snaith-Hamilton Pleasure Scale (SHAPS) total score from baseline to week 6

    The SHAPS is a subject self- administered scale to measure hedonic capacity which consists of 14 items (total scores range from 0 to 14). Each item has a set of 4 possible responses (Strongly or Definitely Agree, Agree, Disagree and Strongly Disagree). A total score is derived by summing the responses to each item. A higher score represents a higher level of anhedonia.

    Time frame: Baseline to Week 6

  3. Change in Montgomery- Åsberg Depression Rating Scale (MADRS) total score from baseline to week 1

    The MADRS is a clinician- rated scale to assess depressive symptoms which consists of 10 items. Each item is scored on 7-point scale (0 \[absence of symptoms\] to 6 \[severe\]). A higher score represents a higher severity of the level of depression (total scores range from 0 to 60).

    Time frame: Baseline to Week 1

  4. Change in Snaith-Hamilton Pleasure Scale (SHAPS) total score from baseline to week 1

    The SHAPS is a subject self- administered scale to measure hedonic capacity which consists of 14 items (total scores range from 0 to 14). Each item has a set of 4 possible responses (Strongly or Definitely Agree, Agree, Disagree and Strongly Disagree). A total score is derived by summing the responses to each item. A higher score represents a higher level of anhedonia.

    Time frame: Baseline to Week 1

  5. Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q- LES-Q-SF) total score

    The Q-LES-Q-SF is a participant self-administered scale to assess the degree of enjoyment and satisfaction experienced in various areas of daily functioning. The form consists of 16 items. Each item is scored on 5-point scale. A higher score represents a higher level of satisfaction and enjoyment (total scores range from 14 to 70).

    Time frame: Baseline to Week 6

  6. Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medication

    Safety and tolerability of BHV-7000 as assessed by frequency of unique subjects with SAEs; AEs leading to discontinuation; AEs judged to be related to study medication

    Time frame: Screening through Week 8

  7. Number of Participants With Clinically Significant Laboratory Abnormalities

    To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 or 4 laboratory abnormalities.

    Time frame: Screening through Week 8

  8. Number of Participants With Vital Sign Abnormalities

    Time frame: Screening through Week 8

  9. Number of Participants With Electrocardiogram (ECG) Abnormalities specific to QTc elevation

    Time frame: Screening through Week 8

07

Study locations

62 sites
  • IMA Clinical Research
    Phoenix, Arizona 85012, United States
  • Pillar Clinical Research, LLC
    Little Rock, Arkansas 72204, United States
  • WIRG
    Little Rock, Arkansas 72211, United States
  • WRN
    Rogers, Arkansas 72758, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • CIT LA
    Bellflower, California 90706, United States
  • IPMG
    Chino, California 91710, United States
  • WR-PRI Encino
    Encino, California 91316, United States
  • Collaborative Neuroscience Research, LLC (CenExel - CNS)
    Garden Grove, California 92845, United States
  • CalNeuro Research Group
    Los Angeles, California 90025, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • CIT IE
    Riverside, California 92506, United States
  • Lumos Clinical Research Center
    San Jose, California 95124, United States
  • Stanford
    Stanford, California 94305, United States
  • Cenexel CNS
    Torrance, California 90504, United States
  • Pacific Clinical Research Management Group
    Upland, California 91786, United States
  • Sunwise Clinical Research
    Walnut Creek, California 94596, United States
  • MCB Clinical Research Centers
    Colorado Springs, Colorado 80910, United States
  • UConn Health
    Farmington, Connecticut 06030, United States
  • Optum Behavioral Care of Connecticut, PC dba Comprehensive Psychiatric Care of Connecticut
    Norwich, Connecticut 06360, United States
  • Clinical Neuroscience Solutions, Inc
    Jacksonville, Florida 32256, United States
  • Floridian Neuroscience Institute
    Miami Lakes, Florida 33016, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • K2 Medical Research
    Tampa, Florida 33607, United States
  • Neuroscience Research Institute
    West Palm Beach, Florida 33407, United States
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Revive Research Institute, Inc.
    Elgin, Illinois 60123, United States
  • Collective Medical Research
    Overland Park, Kansas 66210, United States
  • Delricht Research
    New Orleans, Louisiana 70115, United States
  • Headlands Pharmasite
    Baltimore, Maryland 21208, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • Copley Clinical
    Boston, Massachusetts 02116, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Adams Clinical
    Watertown, Massachusetts 02472, United States
  • Precise Clinical Research
    Flowood, Mississippi 39232, United States
  • Arch Clinical Trials
    St Louis, Missouri 63141, United States
  • IMA Clinical Research
    Las Vegas, Nevada 89102, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Neurobehavioral Research, Inc
    Cedarhurst, New York 11516, United States
  • Bioscience Research LLC
    Mount Kisco, New York 10549, United States
  • Berman Clinical
    New York, New York 10029, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • RBA
    Staten Island, New York 10329, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Scranton Medical Institute
    Moosic, Pennsylvania 18509, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Donald J. Garcia, MD, PA dba Austin Clinical Trial Partners
    Austin, Texas 78737, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75234, United States
  • Relaro Medical Trials, LLC
    Dallas, Texas 75243, United States
  • InSite Clinical Research, LLC
    DeSoto, Texas 75115, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77373, United States
  • Aim Trials
    Plano, Texas 75093, United States
  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
  • Alpine Reseach Organization
    Clinton, Utah 84015, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Nov 2025, 17 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 17 months is close to that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 17, 2024
StartActual
May 28, 2024
Primary completionActual
Nov 7, 2025
CompletionActual
Nov 7, 2025
Results delay requested
Oct 10, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and registry dates
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06419608
Lead sponsor
Biohaven Therapeutics Ltd.
Responsible party
Sponsor
First posted
May 17, 2024
Start date
May 28, 2024
Primary completion
Nov 7, 2025
Completion
Nov 7, 2025
Last update
Oct 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opakalim

Start the discussion